# Aclaris Therapeutics to Participate in Two February Healthcare Conferences
Canonical URL: https://biopharmsignal.com/news/ACRS/aclaris-therapeutics-to-participate-in-two-february-healthcare-conferences-29d11194
Ticker: ACRS
Company: Aclaris Therapeutics
Source: Aclaris Therapeutics
Published: 2026-02-04 12:00 EST
## Summary

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will participate in two upcoming healthcare conferences in F

## Article Body
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will participate in two upcoming healthcare conferences in February 2026.

On Thursday February 12, 2026, at 2:30 PM EST, Aclaris’ Chief Executive Officer Dr. Neal Walker and other members of Aclaris’ senior leadership team will participate in a fireside chat during the Guggenheim Emerging Outlook: Biotech Summit 2026 in New York, NY.

On Thursday February 26, 2026, at 8:40 AM EST, Aclaris’ President and Chief Operating Officer Hugh Davis, Ph.D. will provide a corporate presentation during the virtual Oppenheimer 36 th Annual Healthcare Life Sciences Conference.

A live and archived webcast of both events will be accessible on the Events page of https://www.aclaristx.com/ . The webcasts will be available on the Aclaris website for at least 30 days.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn .

Aclaris Therapeutics Contact:

Will Roberts Senior Vice President Corporate Communications and Investor Relations (484) 329-2125 wroberts@aclaristx.com
## Recent Company News
- 2026-05-28 12:30 EST — [Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/ACRS/aclaris-therapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conf-a0a234d5) — Source: Aclaris Therapeutics
- 2026-05-08 12:30 EST — [Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference](https://biopharmsignal.com/news/ACRS/aclaris-therapeutics-to-participate-in-the-2026-bank-of-america-healthcare-confe-33f392b6) — Source: Aclaris Therapeutics
- 2026-05-07 10:59 EST — [Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update](https://biopharmsignal.com/news/ACRS/aclaris-therapeutics-reports-first-quarter-2026-financial-results-and-provides-c-c157b37c) — Source: Aclaris Therapeutics
- 2026-04-28 10:30 EST — [Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication for ATI-2138, an Oral ITK/JAK3 Inhibitor](https://biopharmsignal.com/news/ACRS/aclaris-therapeutics-announces-positive-full-top-line-first-in-human-results-fro-968484cf) — Source: Aclaris Therapeutics
- 2026-04-27 20:45 EST — [Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026](https://biopharmsignal.com/news/ACRS/aclaris-therapeutics-to-provide-clinical-update-on-key-biologic-and-oral-inhibit-c67a7f91) — Source: Aclaris Therapeutics
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)